Evidence map›Paper›PMID 42234828›Full record

ReviewESC heart failure2026

Diagnostic challenges in isolated cardiac sarcoidosis.

Gregorio Tersalvi, Valentina A Rossi, Moritz Hundertmark, Vittorio Beltrani, Felicitas Escher, Katharina Wörgötter, Stephan Dobner, Felicia C Thianich, Giorgio Treglia, Heinz-Peter Schultheiss and 6 more

Abstract readReview
In one paragraph

Review in ESC heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Gregorio TersalviDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-1845-1777
Valentina A RossiUniversity Heart Center, University Hospital of Zurich, Zurich, Switzerland.
Moritz HundertmarkDepartment of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Vittorio BeltraniDepartment of Cardiology, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Felicitas EscherDeutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Virchow Klinikum, Berlin, Germany.
Katharina WörgötterMedical Faculty, Sigmund Freud University, Freudplatz 3, 1020 Vienna, Austria.
Stephan DobnerMedical Faculty, Sigmund Freud University, Freudplatz 3, 1020 Vienna, Austria.
Felicia C ThianichMedical Faculty, Sigmund Freud University, Freudplatz 3, 1020 Vienna, Austria.
Giorgio TregliaFaculty of Biomedical Sciences, Università Della Svizzera Italiana (USI), Lugano 6900, Switzerland.ORCID 0000-0001-9808-780X
Heinz-Peter SchultheissInstitute for Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany.ORCID 0000-0002-2185-3710
Kurt HuberAustrian Heart Foundation, Vienna, Austria.ORCID 0000-0003-1695-3378
Michele MartinelliDepartment of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Gerhard PölzlDepartment of Cardiology, University Hospital Innsbruck, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0002-2588-6739
Andrew N RosenbaumDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Omar F AbouEzzeddineDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-3256-3660
Martin R GrüblerMedical Faculty, Sigmund Freud University, Freudplatz 3, 1020 Vienna, Austria.ORCID 0000-0002-1761-2914

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Isolated cardiac sarcoidosis (iCS), defined by granulomatous inflammation limited to the myocardium, represents the most diagnostically challenging and prognostically adverse form of sarcoidosis. As it is fundamentally a diagnosis of exclusion, iCS diagnosis relies on the absence of extracardiac sarcoid and the integration of multimodality imaging, endomyocardial biopsy, and molecular testing, each with inherent limitations. Cardiac magnetic resonance and positron emission tomography provide complementary assessment of inflammation, fibrosis, and ventricular function, enhancing diagnostic confidence. Electroanatomic mapping-guided biopsy may improve histologic yield, whereas genetic testing helps exclude phenocopies such as arrhythmogenic, hypertrophic, or dilated cardiomyopathies. Circulating biomarkers remain non-specific but may complement imaging-based algorithms. Future research should focus on harmonized imaging protocols, non-FDG radiotracers, and molecular tissue profiling to refine activity assessment and guide therapy. Multimodal, probability-based frameworks represent the most promising approach for earlier, more accurate diagnosis and risk stratification in iCS.

Indexed as

CardiomyopathiesMagnetic Resonance Imaging, CineMultimodal ImagingMyocardiumSarcoidosisBiopsyHumansPositron-Emission TomographyCardiac sarcoidosisDiagnostic algorithmsElectroanatomic mappingMultimodality imagingPrecision medicine

Identifiers

PMID42234828
PMCPMC13282900

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.